Great, not only doesn’t it work (unlike Ivermectin which does cure Covid) it could cause new variants. Why doesn’t the government and Pharmaceutical industry just try to cure it instead of keeping it going? Oh right, there is no money in curing the disease. There is no control when the country is free and the money is in creating new patients.
Why doesn’t the media call them to task and report the facts? Oh right, they are the propaganda arm of the government.
Why is social media banning scientists who know the truth? Oh right, curing it would end the crisis, the money and the control.
Why do they keep the vaccine lie going?
Why isn’t Fauci put on trial? See at the end.
Discussion surrounding Merck’s newly-authorized COVID-19 pill, molnupiravir, has mostly concerned the risk it might pose to pregnant women. But some experts worry it could also lead to the outbreak of a new variant of the virus it’s designed to treat.
The Food and Drug Administration (FDA) granted emergency use authorization to two antiviral pills to treat COVID-19 this week, one from Pfizer (paxlovid) and another from Merck (molnupiravir). The Pfizer EUA was generally lacking in controversy, but the authorization of molnupiravir was far more contentious.
The FDA’s Antimicrobial Drugs Advisory Committee (ADAC) voted at the end of November to recommend authorization of molnupiravir, but it was by a narrow 13-10 margin. Even the members who voted in favor did so with qualifiers: some said the pill shouldn’t be given to pregnant women, and others were skeptical of its efficacy.
“I don’t think I would want to take this drug, not knowing the effect it could have on my unborn child,” Dr. Roblena Walker, CEO of public health non-profit EMAGAHA Inc. and ADAC member, said at the time. She voted yes.
Some of the members who voted against recommending authorization expressed more serious concerns, that rather than help solve the pandemic with its 30% efficacy rate, molnupiravir could cause the breakout of a new variant.
Molnupiravir works by triggering mutations in the virus of an infected individual, and those mutations go on to eventually kill the infection, Dr. Peter Weina told the Daily Caller. Weina, an infectious disease specialist and director of the Defense Health Agency, is an ADAC member who voted against recommending authorization.
“The drug works by mutating the organism, and this is an organism in which we have a lot of mutations creating problems for us already,” Weina said. “Just like influenza and just like a lot of viruses, there’s a baseline relatively high mutation rate in these viruses. The fact is that most mutations are probably lethal to the organism, but a couple of them are going to end up being beneficial for the organism, and we’ve seen that with the successive different variants that have come out.”
In other words, while the overwhelming majority of mutations triggered by molnupiravir will do their job and kill the virus, its not inconceivable that one of those mutations could be beneficial to COVID-19 and lead to another dangerous variant…….
Click above for more.